Barinthus Biotherapeutics plc (BRNS) ADR Each Rep 1 Ord Share Spon

Sell:$1.30Buy:$1.32$0.02 (1.50%)

Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.32
Change:$0.02 (1.50%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.30
Buy:$1.32
Change:$0.02 (1.50%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Key people

William J. Enright
Chief Executive Officer, Principal Financial Officer, Director
Geoffrey Lynn
Chief Scientific Officer
Leon Hooftman
Chief Medical Officer
Robin Wright
Non-Executive Independent Chairman of the Board
Alex Hammacher
Non-Executive Director
Karen T. Dawes
Non-Executive Independent Director
Pierre A. Morgon
Non-Executive Independent Director
Anne M. Phillips
Non-Executive Independent Director
Click to see more

Key facts

  • Shares in issue
    40.23m
  • EPIC
    BRNS
  • ISIN
    US91864C1071
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $54.30m
  • Employees
    105
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.